AWA
AUTL

Arkadios Wealth Advisors’s Autolus Therapeutics AUTL Stock Holding History

Arkadios Wealth Advisors’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,000
Closed -$47K – 1137
2024
Q4 		$47K Buy
+20,000
New +$67.6K ﹤0.01% 906
2021
Q1 		– Sell
-47
Closed – – 1638
2020
Q4 		$0 Buy
+47
New +$501 ﹤0.01% 1361

Other funds holding AUTL

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Arkadios Wealth Advisors's AUTL Position: Q1 2025 in Review

Arkadios Wealth Advisors sold out of Autolus Therapeutics (AUTL) in Q1 2025, closing a stake of 20,000 shares — an estimated $47K sold.

Arkadios Wealth Advisors first reported a position in AUTL in Q4 2020 and held it in 2 quarters. The position peaked at $47K in Q4 2024. 95 funds tracked by Wall St. Rank hold AUTL as of Q1 2025.

  • Arkadios Wealth Advisors reported no remaining Autolus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Arkadios Wealth Advisors sold 20,000 Autolus Therapeutics shares in Q1 2025, an estimated $47K.
  • Arkadios Wealth Advisors first reported a position in Autolus Therapeutics in Q4 2020 and held it in 2 quarters.
  • Arkadios Wealth Advisors's Autolus Therapeutics position peaked at $47K in Q4 2024.
  • 95 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q1 2025.

Based on Arkadios Wealth Advisors's 13F filing for Q1 2025, filed 8 May 2025.